INTRODUCTION
============

Genomic imprinting is defined by genotype-independent expression from either the maternal or paternal allele. This parent-of-origin expression is mediated by epigenetic modifications that differ between the two parental chromosomes ([@gks1355-B1]). There are currently more than 60 imprinted genes in humans, which are largely conserved in mouse ([@gks1355-B2]; <http://igc.otago.ac.nz/home.html>). Human diseases associated with cytogenetic abnormalities or (epi)mutations, such as transient neonatal diabetes mellitus (TNDM) and Beckwith--Wiedemann, Silver--Russell, Angelman and Prader--Willi syndromes, and targeted mouse experiments have revealed that imprinted genes are essential for foetal and postnatal growth and behaviour, with aberrant expression in adults associated with multigenic diseases and cancer ([@gks1355-B3]).

Imprinted genes are regulated by *cis*-acting imprinting control regions (ICRs), which manifest as regions of allelic DNA methylation that are set during gametogenesis and are inherited throughout somatic development by the action of the DNMT1 complex ([@gks1355-B9]). These differentially methylated regions (DMRs) are associated with a canonical chromatin signature, which comprises H3 lysine 9 trimethylation and H4 lysine 20 trimethylation on the DNA-methylated allele, whereas H3 lysine 4 methylation is associated with the unmethylated allele and may confer protection from *de novo* DNA methylation ([@gks1355-B12]).

Imprinted genes rarely occur in isolation, as monoallelic expression is achieved by shared *cis*-regulatory elements that act in distinct ways at different loci (reviewed in [@gks1355-B1]). Despite information from a few well-studied loci, still little is known how ICRs silence neighbouring genes, and there seems to be two prevailing models of regulation. In general, paternally methylated intergenic ICRs act as methylation-sensitive insulators recruiting CTCF ([@gks1355-B13]), while the majority of maternally methylated ICRs act as promoters. In some cases, these differentially methylated promoters are associated with long non-coding RNAs that confer silencing of neighbouring genes in *cis* through recruitment of histone-remodelling complexes ([@gks1355-B14],[@gks1355-B15]). However, for the majority of imprinted domains, the intricacies of ICR action are unknown, and novel mechanisms, such as allele-specific alternative polyadenylation choice, are continuously updating our insight on imprinted regulation ([@gks1355-B16]). Imprinted domains are especially attractive to researchers as they permit the study of inherited epigenetic transcriptional regulation, as both the active and silent alleles are genetically identical and are present within the same nucleus, exposed to the same *trans*-acting chromatin regulators.

To date, the imprinted domain on human chromosome 6 associated with TNDM contains two paternally expressed transcripts, *PLAGL1* (previously known as *ZAC1*) and the non-coding RNA *HYMAI*, both initiating from within the maternally methylated *PLAGL1*-DMR ([@gks1355-B17],[@gks1355-B18]). To determine whether these transcripts are part of a larger imprinting cluster, we performed allelic expression analysis of the flanking genes in both human and mouse. This revealed that the region is a micro-imprinted domain, as all surrounding transcripts are biallelically expressed in both species, including *PHACTR2*, which we show exhibits allelic bias in human placenta associated with genotype and not parental origin ([@gks1355-B19]). Interrogation of publicly available CTCF ChIP-seq data shows that *PLAGL1* is flanked by CTCF-binding sites conserved between species in both expressing and non-expressing cells. These two CTCF/cohesin regions interact physically despite being separated by more than 70 kb, and we propose this restricts imprinting to only those transcripts contained within the chromatin loop.

MATERIALS AND METHODS
=====================

Human tissues
-------------

A cohort comprising 65 foetal tissue sets (8--18 weeks) with corresponding maternal blood samples and 96 term placental samples from the Moore Tissue bank are described elsewhere ([@gks1355-B20]). An additional 96 human placenta samples were collected at Hospital St Joan De Deu (Barcelona, Spain). DNA and RNA extraction and cDNA synthesis were carried out as previously described ([@gks1355-B21]). A selection of normal adult brain samples was obtained from BrainNet Europe/Barcelona Brain Bank. The human RNA panel was purchased from Clontech (Human Total RNA master Panel II). Ethical approval for adult blood and foetal tissue collection was granted by the Hammersmith, Queen Charlotte's & Chelsea and Acton Hospital Research Ethics Committee (Project Registration 2001/6029 and 2001/6028); collection of the HSJD placental cohort was granted by the ethical committee of Hospital St Joan De Deu (Study Number 35/07) and IDIBELL (PR006/08). Written informed consent was obtained from all participants.

Mouse crosses and cell lines
----------------------------

To determine allelic expression in mouse, wild-type embryos and placentas were produced by crossing C57BL/6 (B) with *Mus musculus castaneus* (C) mice. RNA and DNA were isolated and extracted as previously described ([@gks1355-B10]). Control lymphoblastoid cell lines were established by Epstein--Barr virus transformation of peripheral blood cells and propagated as previously described ([@gks1355-B22]). Before chromatin immunoprecipitation (ChIP), the lymphoblastoid methylation signature throughout the *PLAGL1* domain was compared with leucocytes to ensure that the transformation process had not altered the epigenetic profile. The human TCL1 placental trophoblast cell line was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics.

Allelic expression analysis
---------------------------

Genotypes were obtained in the foetal and placental tissues for expressed genes using PCR and direct sequencing. Sequences were interrogated using Sequencher v4.6 (Gene Codes Corporation, MI) to distinguish heterozygous and homozygous samples. Heterozygous sample sets were analysed for allelic expression using RT-PCR that incorporated the polymorphisms in the final PCR product ([Supplementary Table S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)). The resulting RT-PCR amplicons were sequenced in both directions. The amplification cycle number for each transcript was determined to be within the exponential phase of the PCR, which varied for each gene, but was between 32 and 40 cycles.

Pyrosequencing analysis for allelic expression quantification
-------------------------------------------------------------

Pyrosequencing was used as an accurate method of quantifying allelic expression of *PHACTR2* in heterozygous placenta samples. Standard RT-PCR was used to amplify across two independent single nucleotide polymorphisms (SNPs) mapping to exon 6 (an alternative spliced exon) and the 3′ UTR, with the exception that the reverse primers were biotinylated. The entire biotinylated RT-PCR product (diluted to 40 µl) was mixed with 38 µl of binding buffer and 2 µl (10 mg/ml) of streptavidin-coated polystyrene beads. Bead--amplicon complexes were captured on a vacuum prep tool (Qiagen), and the PCR products denatured using 0.2 M NaOH. The denatured DNA was resuspended in 40 pmol of sequencing primer dissolved in 12 µl of water, and primer annealing was achieved by heating the sample to 80°C for 2 min before cooling to room temperature. For sequencing, forward primers were designed to the complementary strand ([Supplementary Table S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)). The pyrosequencing reaction was carried out on a PyroMark Q96 instrument. The peak heights were determined using the pyrosequencing commercial software.

Real-time RT-PCR
----------------

All PCR amplifications were run in triplicate on either an Applied Biosystems 7500 or 7900 Fast real-time PCR machines (Applied Biosystems) following the manufacturers' protocol. All primers were optimized using SYBR Green ([Supplementary Table S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1) for *PLAGL1* primers, all other genes were amplified using KiCqStart primers from Sigma-Aldrich), and melt curve analysis was performed to ensure that amplicons were specific and free of primer-dimer products. Thermal cycle parameters included *Taq* polymerase activation at 95°C for 10 min for one cycle, repetitive denaturation at 95°C for 15 s and annealing at 60°C for 1 min for 40 cycles. All resulting triplicate cycle threshold (Ct) values had to be within 1 Ct of each other. The quantitative values for each triplicate were determined as a ratio with the level of *RPL19* expression, which was measured in the same sample.

Analysis of allelic DNA methylation
-----------------------------------

The DNA methylation profile throughout the *PLAGL1* domain was determined using published data from our previous Illumina Infinium HumanMethylation27 BeadChIP array analysis (GEO accession number: GSE 28525) ([@gks1355-B23]). Promoter regions not included on this array platform were assessed by conventional bisulphite PCR. Approximately 1 µg of DNA was subjected to sodium bisulphite treatment and purified using the EZ GOLD methylation kit (ZYMO, Orange, CA) and was used for all bisulphite PCR analysis. Bisulphite PCR primers for each region were used with Hotstar Taq polymerase (Qiagen, West Sussex, UK) at 45 cycles, and the resulting PCR product was cloned into pGEM-T easy vector (Promega) for subsequent sequencing (see [Supplementary Table S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)).

Chromatin immunoprecipitation
-----------------------------

We used previously published CTCF ChIP-seq data sets for leucocytes and CD34 cells (GEO accession number: GSM651541) and chromatin interaction analysis with paired-end tags (ChIA-PET; GEO accession number: GSM970213 and GSM970216) (<http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcell.aspx>) to identify potential binding sites within the 6q24-imprinted domain. For ChIP, chromatin from ∼80 million cells was aliquoted into 100-µg batches and used for each immunoprecipitation reaction with Protein A Agarose/Salmon Sperm DNA (Millipore, 16-157) and specific antibody. The antibody against CTCF (07-729) was obtained from Millipore, and the antibodies against RAD21 (AB992) and SMC3 (AB9263) were obtained from ABCAM. For each ChIP, a fraction of the input chromatin (1%) was also processed for DNA purification, and a mock immunoprecipitation with a neutral unrelated IgG antiserum was carried out in parallel.

Levels of immunoprecipitated chromatin at specific region were determined by qPCR using an Applied Biosystems 7900 Fast real-time PCR machine, using SYBR Green (Applied Biosystems). Each PCR was run in triplicate, and protein binding was quantified as a percentage of total input material. Normalization of ChIP levels was performed by comparing precipitation levels obtained for each specific region of interest with the level obtained for a known CTCF/cohesin-positive control region mapping to chromosome 6 ([@gks1355-B24]) (see [Supplementary Table S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1) for primer sequences).

Chromatin conformation capture analysis
---------------------------------------

The chromatin conformation capture (3C) protocol was performed as previously described ([@gks1355-B25]), with minor amendments. Briefly, HindIII was used to digest 1 × 10^7^ formaldehyde--cross-linked nuclei from leucocytes, placental cell line TCL1, mouse embryonic fibroblasts (MEFs) (for which EcoR1 was used) or 100 mg of archived tissue (overnight digestion, 1200 U, NEB). The efficiency of the restricted enzyme digestion was assessed by qPCR across each restriction site, comparing digested and undigested chromatin fractions. Only chromatin with digestion efficiency more than 70% was used. Subsequently, the DNA was ligated overnight in a 500-ul reaction volume using 1950 units of T4 ligase (Fermentas). DNA was de--cross-linked by incubating overnight at 65°C and purified using phenol/chloroform extraction. This DNA was used for both nested PCR for analysis of allelic interactions, and real-time PCR (LightCycler, Roche Applied Science) to determine the frequency of interactions, using constant primers either in the unmethylated regions ∼5 kb upstream from the DMR, within the last *PLAGL1* exon, or between the P3/P4 promoters (see [Supplementary Table S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)). Primer efficiency and basal interaction frequencies were determined using digested and ligated bacterial artificial chromosomes (BAC) DNA (human RPII RP11 947A22; mouse RP24 399D18) as described by Braem and co-workers ([@gks1355-B26]). All 3C experiments were performed in at least 3 biological samples per tissue in technical triplicates.

RESULTS
=======

*PLAGL1* and */HYMAI* are the only imprinted genes mapping to 6q24
------------------------------------------------------------------

To characterize the boundaries of the imprinted region on human chromosome 6, we determined the abundance and allele-specific expression of nine genes flanking *PLAGL1* (*DEADC1*, *PEX3*, *FUCA2*, *PHACTR2*, *LTV1*, *SF3B5*, *STX11*, *BC033369/LOC285740* and *UTRN*) using RT-PCR amplification across transcribed SNPs in first trimester foetal tissues and term placenta. No SNPs were identified within *FAM164B*. We confirm that human *PLAGL1* transcripts from the P1 promoter and *HYMAI* were paternally expressed in all tissues analysed at all gestational ages. The *PLAGL1* expression from the P2 promoter was biallelic when detectable. Biallelic expression of the remaining transcripts was observed in all tissues analysed, and their associated promoters were unmethylated ([Figure 1](#gks1355-F1){ref-type="fig"}A and B; [Supplementary Figures S1](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1) and [S2](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1); [Supplementary Table S2](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)). Figure 1.Schematic representation of the *PLAGL1* domain on human chromosome 6p24. (**A**) The relative organization of the human genes and CpG islands. The orthologous mouse domain has a similar organization, except the lack of the non-coding RNA *LOC285740*. (**B**) The allelic expression for all genes in the human cluster. The sequence traces for heterozygous DNA samples from term placentas are shown for all genes, as well as the resulting RT-PCR. Black boxes depict genes that are expressed biallelically in all tissues throughout gestation, whereas blue boxes represent ubiquitously imprinted, paternally expressed transcripts. (**C**) A comparison of the structure and position of the imprinted transcripts within the *Plagl1/PLAGL1* transcriptional unit, including the location of the CTCF sites. (**D**) DNA sequences across rs2076684 SNP in the penultimate *PLAGL1* exon and the RT-PCR sequence traces for each isoform in term placenta.

To assess the imprinting profile within the mouse orthologous region on chromosome 10, we used various embryonic tissues and placenta (at embryonic stage E14.5) from reciprocal crosses between C57BL/6 (B) and *Mus musculus castaneus* (C). We confirm the ubiquitous imprinting previously described for the paternally expressed *Plagl1* transcript, and observed equal expression from both parental alleles for all other genes ([Supplementary Figure S3](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)).

Conserved paternally expressed *PLAGL1* isoforms
------------------------------------------------

We recently identified and characterized several paternally expressed *Plagl1* alternative transcripts in mouse ([@gks1355-B27]) ([Figure 1](#gks1355-F1){ref-type="fig"}C). One of these transcripts, originating from the P3 promoter region, results in a transcript containing the protein-coding exons. As a result of expressed sequence tag (EST) and mRNA alignments, we identified an orthologous transcript originating from the equivalent P3 promoter region in the human. This transcript (reference EST AJ006354) originates from a unique promoter region 5′ to the exon 6 acceptor site (tctcacag/GTTTGAAT or tgtacaag/GTCTCTTC) of the P1-*PLAGL1* transcript, with a 5′ UTR that extends at least 800 bp into the upstream intron. In addition, we identified another transcript originating from a novel promoter region ∼3.5 kb upstream of the P3 promoter, located 5′ to the exon 5 acceptor site (ctttctag/GTATTTGC) of P1-*PLAGL1* transcript, which we named P4-*PLAGL1* ([Figure 1](#gks1355-F1){ref-type="fig"}C). The resulting transcript (reference EST AK091707) also includes the full open reading frame. Both of these promoter regions can produce transcripts with alternative splicing of the penultimate exon, which results in protein lacking the first two zinc finger domains. These transcripts are evident on the northern blot analysis performed by Kas *et al.* ([@gks1355-B28]) using a probe encompassing last exon of *PLAGL1*. Using strategically positioned RT-PCR primers, we were unable to link these unique 5′ UTRs with exons 1--3 of P1-*PLAGL1*, confirming that these are independent transcripts. Consistent with this, we observe that P1-*PLAGL1* expression was higher than all other isoforms in a panel of foetal and adult tissues ([Supplementary Figure S4](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)), with all transcripts being most plentiful in placenta and absent in leucocytes. Using an SNP located within exon 7, we show that these novel isoforms are paternally expressed in placenta (*n* = 11) and monoallelically expressed in brain (*n* = 2) ([Figure 1](#gks1355-F1){ref-type="fig"}C and D).

Human *PHACTR2* exhibits genotype-associated allelic expression in placenta
---------------------------------------------------------------------------

Partial imprinting of *PHACTR2* has been described in some term placentas, with maternal bias observed for the SNP rs1082 within the 3′ UTR of the gene. The expression levels of *PHACTR2* were reported to be lower in heterozygous placentas compared with homozygous samples, suggesting that the genotype could play a role in the allelic bias ([@gks1355-B19]). Using both standard Sanger DNA sequencing and quantitative pyrosequencing, we also observed a range of allelic profiles for rs1082, consistent with previous reports. However, on assessing a second SNP (rs2073214) within exon 6 of *PHACTR2*, three placental samples showed equal expression from both parental alleles, whereas 17 had strong preferential/monoallelic expression of the T allele. Subsequent genotyping of maternal DNAs corresponding to these samples identified two placentas with expression from the paternal allele, revealing that the monoallelic expression observed is not due to imprinting but presumably SNP-associated regulation ([Supplementary Figure S5](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)).

CTCF/cohesin form non-allelic boundaries flanking *PLAGL1*
----------------------------------------------------------

In an attempt to understand the mechanism restricting imprinting to *HYMAI* and the *PLAGL1* transcripts, we interrogated genome-wide CTCF data sets to identify potential CTCF boundaries. Using two published data sets ([@gks1355-B29],[@gks1355-B30]), we identified two regions of strong CTCF binding, one ∼5 kb downstream of the *PLAGL1*-DMR and between this and the non-imprinted P2 promoter, and the other within the last exon of *PLAGL1*. This latter region showed two independent CTCF peaks ∼2 kb apart ([Figures 1](#gks1355-F1){ref-type="fig"}C and 2). Using PCR on bisulphite-converted DNA, we were able to show that the CpG dinucleotides surrounding these CTCF-binding sites are unmethylated in leucocyte- and placenta-derived DNA ([Figure 2](#gks1355-F2){ref-type="fig"}B). Comparison of the sequence surrounding these binding sites identified CTCF consensus sites that contain both motifs (M1 and M2) recently described by Schmidt and co-workers ([@gks1355-B31]). The M1 motifs of both regions contain CpG dinucleotides, which ensure methylation-sensitive binding. Interestingly, the second binding site within the last *PLAGL1* exon (region 6, [Figure 2](#gks1355-F2){ref-type="fig"}) lacks the M2 motif and CpG dinucleotides (data not shown). Figure 2.DNA methylation and ChIP of CTCF, RAD21 and SMC3 analysis throughout the *PLAGL1* locus. (**A**) The localization of the bisulphite PCR and ChIP regions analysed. (**B**) Bisulphite sequence in placenta- and leucocyte-derived DNA. Each circle represents a single CpG dinucleotide on the strand: (filled circle) a methylated cytosine, (open circle) unmethylated cytosines. (**C**) qPCR performed on CTCF, RAD21 and SMC3 ChIP material in normal lymphoblastoid cells at various regions across the *PLAGL1* domain. (**D**) Sequence traces showing monoallelic precipitation of CTCF and cohesion subunits at the control *H19*-ICR domain and biallelic precipitation at region 6 mapping within the *PLAGL1* 3′ UTR.

Subsequent ChIP using antisera to CTCF was performed to confirm binding in lymphoblastoid cells and the placental cell line TCL1. We observed strong CTCF enrichment within the regions downstream of the *PLAGL1*-DMR and in the last exon, but not within the *PLAGL1*-DMR itself or in the regions overlapping the P3 and P4 promoters ([Figure 2](#gks1355-F2){ref-type="fig"}C; data not shown). Recently, cohesin has been shown to play a critical role in maintaining CTCF higher-order chromatin conformation at the *H19-IGF2* loci ([@gks1355-B32]). To determine whether CTCF and cohesin co-localize within the *PLAGL1* regions, we performed ChIP using antisera against the cohesin subunits RAD21 and SMC3 ([Figure 2](#gks1355-F2){ref-type="fig"}C). In lymphoblastoiod cell lines, the cohesin subunits clearly precipitated with CTCF on one allele at the *H19*-ICR control region, and on both chromosomes throughout the *PLAGL1* domain ([Figure 2](#gks1355-F2){ref-type="fig"}D).

The biallelic CTCF regions adjacent to *PLAGL1* physically interact to form chromatin loops
-------------------------------------------------------------------------------------------

Recent studies have revealed that CTCF is a key regulator of chromatin fibre structure and responsible for organizing chromosomal territories within the cell nucleus ([@gks1355-B33],[@gks1355-B34]). To determine whether the CTCF/cohesin sites physically interact, we performed 3C experiments to identify potential chromatin folding. 3C-qPCR assays were performed on adult leucocytes and brain samples, term placenta material and the TCL1cell line, and interaction frequencies were determined between a constant HindIII site located ∼500 bp upstream to the unmethylated CTCF/cohesin binding site 5′ to the *PLAGL1*-DMR and other HindIII sites throughout the locus. We observed high interaction frequencies of sites separated by \<20 kb from the constant fragment, which included the *PLAGL1*-DMR, reflecting non-specific random collision due to their physical proximity. We subsequently identified strong interactions between the CTCF/cohesin constant fragment and the CTCF/cohesin sites in the last *PLAGL1* exon, in different tissues irrespective of expression ([Figure 3](#gks1355-F3){ref-type="fig"}). Direct sequencing of the chimerical products from placenta and brain revealed that the interactions occurred on both chromosomes, and that the appropriate chimeric products result from the 3C ligations ([Figure 3](#gks1355-F3){ref-type="fig"}D and [Supplementary Figure S6](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)). Interrogation of publicly available ChIA-PET ([@gks1355-B35]) data revealed that CTCF mediates an abundant loop identical to the one we identified ([Figure 3](#gks1355-F3){ref-type="fig"}). In addition, we also identified non-allelic interactions between the constant fragment and the HindIII sites associated with the P3/P4 promoter regions in placenta and brain ([Figure 3](#gks1355-F3){ref-type="fig"}B). We did not observe these interactions in leucocytes, which suggests this specific contact occurs only in tissues exhibiting transcription from the P3/P4 promoters and appears independent of CTCF binding. Interestingly, we observed a leucocyte-specific chimeric product between the CTCF/cohesin binding site 5′ to the *PLAGL1*-DMR and a region in intron 1, which may represent a repressive interaction. These interactions were confirmed in two additional 3C experiments using constant primers in the last *PLAGL1* exon ([Supplementary Figure S6](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)) as well as the intervening region between the P3 and P4 promoter ([Figure 3](#gks1355-F3){ref-type="fig"}C). Figure 3.Chromatin interactions with the CTCF sites upstream of the *PLAGL1*-DMR. (**A**) The position of the HindIII sites used for 3C analysis, and annotated ChIA-PET data showing CTCF and POL2 interactions. (**B**) The looping profile in brain (black), placental TCL1 cell line (red) and normal leucocytes (blue) using a constant primer 5 kb upstream of the *PLAGL1*-DMR, showing strong interactions with the 3′ UTR and alternative promoters of *PLAGL1*. The x-axis shows the position of the primers used. (**C**) The interaction profile in expressing tissues, brain (black) and placental TCL1 cell line (red), using a constant primer between the P3 and P4 promoters. (**D**) Heterozygous SNP rs2064661 in constant fragment 5 kb upstream of the *PLAGL1*-DMR allowed for allele-specific chromatin interactions to be assessed in adult brain. Sequence traces reveal biallelic higher-order chromatin interactions between the constant fragment and various contact points throughout the *PLAGL1* domain.

CTCF sites at conservation locations physically interact in the mouse
---------------------------------------------------------------------

Because the allelic expression patterns were similar between human and mouse for genes surrounding *PLAGL1/Plagl1*, we predicted that the higher-order chromatin structure will be comparable. Interrogation of the mouse transcription factor binding site (TFBS) data set from ENCODE (data available on the UCSC browser, NCBI37/mm9 assembly) identified two regions of strong CTCF binding at similar locations as in human ([Figure 1](#gks1355-F1){ref-type="fig"}). To confirm that these sites interact to form a chromatin loop, we performed allelic 3C on mouse embryonic fibroblast cells. This semi-quantitative analysis revealed a biallelic contact between an EcoRI constant fragment containing the CTCF site located ∼4 kb upstream of the *Plagl1*-DMR and the binding site in the last exon ∼40 kb downstream ([Supplementary Figure S7](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gks1355/-/DC1)).

DISCUSSION
==========

By analysing the allelic expression of transcripts flanking *PLAGL1/HYMAI*, we show that this locus is one of only a few true conserved micro-imprinted domains. Previously reported micro-imprinted domains such as *Grb10/GRB10* and imprinted transcripts that result from X-derived retrotransposition into host gene introns have subsequently been shown to influence either neighbouring or host genes ([@gks1355-B36]).

We demonstrate that the imprinted transcriptional unit in both humans and mouse is restricted within CTCF/cohesin boundaries, suggesting that they are associated with a conserved regulatory function. Interestingly, this 70-kb loop is very similar in size to the minimal TNDM critical region identified by micro-duplications ([@gks1355-B39]). By using allelic 3C, we show that the flanking CTCF/cohesin-binding sites physically interact in both species in a biallelic manner. In humans, this confirmation is maintained in both expressing and non-expression tissues, suggesting that the chromatin architecture is maintained by CTCF/cohesin and that additional transcription factors are required to promote expression. This is reminiscent of the CTCF/cohesin long-range interactions observed at the *IGF2-H19* domain in lymphoblastoid cells, a cell type that does not express *IGF2* despite maintained looping ([@gks1355-B22],[@gks1355-B32]). In tissues that abundantly express the predominant P1-*PLAGL1* transcript, we identified novel imprinted isoforms originating 45 kb downstream. The promoter regions of the P3- and P4-*PLAGL1* transcripts are embedded within CpG-poor regions (the upstream 1 kb of P3 and P4 have 12 and 10 CpG dinucleotides, respectively). We hypothesize that the level of transcription from these isoforms is regulated by a combination of the endogenous promoter sequences and shared enhancers with the P1-*PLAGL1* promoter, the latter conferring the allelic specificity. This is supported by the observed CTCF-independent chromatin loop in expressed tissues that juxtaposes the P3/P4 promoters and the *PLAGL1*-DMR so that any methylation-sensitive transcription factor binding at the *PLAGL1-*DMR could influence P3/P4 ([Figure 4](#gks1355-F4){ref-type="fig"}). Analysis of ChIA-PET using CTCF and POL2 revealed that this second chromatin interaction is solely present in the POL2 data set, confirming our observations ([@gks1355-B35]). Figure 4.Proposed model of the chromatin scaffold of the paternal allele in (**A**) expressing and (**B**) non-expressing tissues. In tissues co-expressing transcripts from the P1 and P3/P4 promoters, we speculate that a second chromatin loop unites these regions to share transcription factors.

A meta-analysis of microarray data recently revealed that *Plagl1* is a member of a co-regulated imprinted gene network (IGN) important for embryonic growth ([@gks1355-B40]). The mechanism regulating this IGN remains to be elucidated, and may be directly linked to the Plagl1 protein because it encodes a zinc finger transcription factor ([@gks1355-B41]). Alternatively, it may be speculated that CTCF is a common denominator mediating expression of numerous imprinted loci via intra- and interchromosomal interactions ([@gks1355-B42]). Our results suggest that the TNDM phenotype associated with paternal duplications of 6q24 likely results from the overexpression of *PLAGL1*, the only imprinted protein-coding gene in the region, and it remains to be determined whether *PLAGL1* is central to an IGN important for non-syndromic human growth as in mouse.
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